Insider Selling: ICU Medical, Inc. (NASDAQ:ICUI) CEO Sells 12,000 Shares of Stock

ICU Medical, Inc. (NASDAQ:ICUI - Get Free Report) CEO Vivek Jain sold 12,000 shares of the firm's stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $171.84, for a total transaction of $2,062,080.00. Following the sale, the chief executive officer now directly owns 104,593 shares in the company, valued at $17,973,261.12. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Vivek Jain also recently made the following trade(s):

• On Tuesday, October 1st, Vivek Jain sold 12,000 shares of ICU Medical stock. The stock was sold at an average price of $178.46, for a total transaction of $2,141,520.00.
• On Tuesday, September 3rd, Vivek Jain sold 12,000 shares of ICU Medical stock. The stock was sold at an average price of $163.46, for a total transaction of $1,961,520.00.
• On Friday, August 16th, Vivek Jain sold 12,000 shares of ICU Medical stock. The stock was sold at an average price of $156.04, for a total transaction of $1,872,480.00.

ICU Medical Stock Up 0.7 %

Shares of ICUI traded up $1.18 during mid-day trading on Monday, reaching $172.00. 230,483 shares of the stock traded hands, compared to its average volume of 274,363. The firm has a market cap of $4.20 billion, a price-to-earnings ratio of -58.90 and a beta of 0.66. The stock has a fifty day simple moving average of $174.09 and a 200 day simple moving average of $137.78. ICU Medical, Inc. has a 12-month low of $78.28 and a 12-month high of $188.53. The company has a quick ratio of 1.08, a current ratio of 2.41 and a debt-to-equity ratio of 0.76.

ICU Medical (NASDAQ:ICUI - Get Free Report) last posted its quarterly earnings data on Wednesday, August 7th. The medical instruments supplier reported $1.56 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.00 by $0.56. The company had revenue of $596.50 million for the quarter, compared to analyst estimates of $556.64 million. ICU Medical had a negative net margin of 3.07% and a positive return on equity of 5.01%. The business's quarterly revenue was up 8.6% on a year-over-year basis. During the same quarter last year, the firm posted $1.58 earnings per share. Sell-side analysts expect that ICU Medical, Inc. will post 3.81 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the stock. KeyCorp lifted their price target on shares of ICU Medical from $147.00 to $198.00 and gave the company an "overweight" rating in a research report on Tuesday, October 15th. Raymond James lifted their price target on shares of ICU Medical from $158.00 to $190.00 and gave the company an "outperform" rating in a research report on Thursday, September 12th. Needham & Company LLC reaffirmed a "hold" rating on shares of ICU Medical in a research report on Thursday, October 10th. Jefferies Financial Group assumed coverage on shares of ICU Medical in a research report on Monday, October 14th. They set a "hold" rating and a $183.00 price target on the stock. Finally, StockNews.com raised shares of ICU Medical from a "hold" rating to a "buy" rating in a research report on Thursday, September 12th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to MarketBeat.com, ICU Medical currently has an average rating of "Moderate Buy" and a consensus target price of $170.25.

Institutional Trading of ICU Medical

A number of hedge funds have recently made changes to their positions in the company. Crossmark Global Holdings Inc. purchased a new stake in shares of ICU Medical during the third quarter valued at approximately $313,000. Atria Investments Inc bought a new stake in shares of ICU Medical in the third quarter worth $228,000. Equitable Trust Co. increased its stake in shares of ICU Medical by 2.2% in the third quarter. Equitable Trust Co. now owns 5,213 shares of the medical instruments supplier's stock worth $950,000 after buying an additional 112 shares during the last quarter. Principal Financial Group Inc. increased its stake in shares of ICU Medical by 24.6% in the third quarter. Principal Financial Group Inc. now owns 126,937 shares of the medical instruments supplier's stock worth $23,130,000 after buying an additional 25,031 shares during the last quarter. Finally, Amalgamated Bank increased its stake in shares of ICU Medical by 13.1% in the third quarter. Amalgamated Bank now owns 7,067 shares of the medical instruments supplier's stock worth $1,288,000 after buying an additional 816 shares during the last quarter. Hedge funds and other institutional investors own 96.10% of the company's stock.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.